bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of “Hold” from Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have been given a consensus rating of “Hold” by the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $3.03.

Several brokerages have issued reports on BLUE. StockNews.com started coverage on shares of bluebird bio in a research report on Tuesday. They set a “sell” rating on the stock. JPMorgan Chase & Co. cut bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. Bank of America lowered bluebird bio from a “buy” rating to a “neutral” rating and dropped their target price for the company from $3.00 to $0.50 in a report on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th.

bluebird bio Stock Up 7.2 %

bluebird bio stock opened at $0.41 on Friday. The stock has a 50-day simple moving average of $0.45 and a 200-day simple moving average of $0.74. The company has a market capitalization of $78.75 million, a P/E ratio of -0.22 and a beta of 0.76. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. bluebird bio has a fifty-two week low of $0.29 and a fifty-two week high of $5.53.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The firm had revenue of $18.57 million during the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. Equities research analysts expect that bluebird bio will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On bluebird bio

Large investors have recently made changes to their positions in the stock. Barclays PLC grew its position in bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares during the period. Geode Capital Management LLC boosted its stake in shares of bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after acquiring an additional 166,771 shares in the last quarter. State Street Corp grew its holdings in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after acquiring an additional 43,382 shares during the period. Verition Fund Management LLC purchased a new position in bluebird bio in the 3rd quarter valued at approximately $42,000. Finally, Captrust Financial Advisors raised its holdings in bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 77,293 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.